Palisade Bio, Inc. · NASDAQ:PALI
Palisade Bio — Neuralstem — Investor Presentation (January 2012)
10 slides from Palisade Bio's investor presentation, Jan 12, 2012
Slide 1: Neural Stem Cell Technology Platform for Cell Therapeutics and Pharmaceuticals
Neural Stem Cell Technology Platform for Cell Therapeutics and Pharmaceuticals NYSE Amex: CUR www.neuralstem.com
Slide 2: Safe Harbor Statement
2 NEURALSTEM, INC. SAFE HARBOR STATEMENT This presentation contains forward - looking statements. Neuralstem wishes to caution the readers of and listeners participating in this presentation that actual results may differ from those discussed in the forward - looking statements and may be adversely
Slide 3: Neuralstem Technology: Stem Cells of the Brain and the Spinal Cord
Neuralstem Technology: Stem Cells of the Brain and the Spinal Cord □ Platform technology □ Many cell therapy products □ Regionally specific CNS stem cells □ Patented □ Issued and re - affirmed worldwide □ Fully characterized □ Expanded under defined conditions: no animal - derived reagents, serum or
Slide 4: Platform Cell Therapeutics' Commercialization and Platform Roll-out
Neuralstem Platform Cell Therapeutics’ Commercialization and Platform Roll - out 4 Neuralstem Technology Platform Direct Injection / Transplantation Into the Spinal Cord or Brain Cell Therapy Small Molecule Discovery / Development Enabled by Proprietary Stem Cell - based Screening Pharmaceuticals Am
Slide 5: Neuralstem, Inc.: Snapshot
Neuralstem, Inc.: Snapshot □ Technology platform supports two divisions: □ Cell Therapeutics – Direct cell injection/transplantation to spinal cord or brain □ Pharmaceuticals – Small molecule discovery and development via proprietary stem cell - based screening □ FDA - reviewed cGMP spinal cord stem
Slide 6: ALS Trial: World-Class Trial Design and Execution
Neuralstem ALS Trial: World - Class Trial Design and Execution □ Principal Investigator: Eva L. Feldman, M.D., Ph.D. , Professor of Neurology & Director A. Alfred Taubman Medical Research Institute of the University of Michigan Medical School □ Site Principal Investigator: Jonathan D. Glass, M.D. ,
Slide 7: ALS Phase I Patient Summary
Neuralstem ALS Trial ALS Phase I Patient Summary □ Poster titled “Lumbar intraspinal injection of neural stem cells in patients with ALS: Interim results of a Phase I trial” □ Presented at American Neurological Association Annual Meeting, September 2011 7 PATIENT GROUP GENDER AGE AT SURGERY DISEASE
Slide 8: Drug action: proliferation, differentiation, maturation/function
ites ‘ drug action —Comprehensive pote 1. Proliferation 2. Differentiation 3. Maturation/Function ‘Committed | eee ic ‘Mature Neurons team, epee AZ am ‘Neural Stem han 7 on =P Glia Progenitor, 4Mitogen __-Mitogen Increased Cognition/Function
Slide 9: Small Molecule Drug Program Overview
Neuralstem Small Molecule Drug Program Overview □ NSI - 189 □ First in this new class of compounds □ Characteristics: molecular wt. <400, orally active, excellent brain penetration, key biological activity: enhanced neurogenesis and increased hippocampal volume □ Major Depressive Disorder – leading
Slide 10: 2012 Catalysts
Neuralstem, Inc. 2012 Catalysts □ Ongoing Clinical Trials □ ALS □ Phase I cervical - transplantations completion □ Phase II trial application □ NSI - 189 □ Phase Ib trial completion □ Phase IIa trial application in U.S. □ cSCI – Phase I multi - site trial continuing □ New Clinical Trials □ NSI - 189